Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

TD Cowen Downgrades Cerevel Therapeutics Hldg to Market Perform, Announces $45 Price Target

Author: Benzinga Newsdesk | December 08, 2023 06:13am
TD Cowen analyst Joseph Thome downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Outperform to Market Perform and announces $45 price target.

Posted In: CERE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist